{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T07:29:26Z","timestamp":1772782166908,"version":"3.50.1"},"reference-count":29,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":133,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Neurol Scand"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1111\/ane.12413","type":"journal-article","created":{"date-parts":[[2015,4,21]],"date-time":"2015-04-21T10:01:53Z","timestamp":1429610513000},"page":"337-345","source":"Crossref","is-referenced-by-count":12,"title":["Cardiac safety of lacosamide: the non-clinical perspective"],"prefix":"10.1155","volume":"132","author":[{"given":"A.","family":"Delaunois","sequence":"first","affiliation":[{"name":"Non-Clinical Development; UCB Biopharma SPRL.; Braine l'Alleud Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Colomar","sequence":"additional","affiliation":[{"name":"Non-Clinical Development; UCB Biopharma SPRL.; Braine l'Alleud Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. O.","family":"Depelchin","sequence":"additional","affiliation":[{"name":"Non-Clinical Development; UCB Biopharma SPRL.; Braine l'Alleud Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Cornet","sequence":"additional","affiliation":[{"name":"Non-Clinical Development; UCB Biopharma SPRL.; Braine l'Alleud Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,4,21]]},"reference":[{"key":"10.1111\/ane.12413-BIB0001|ane12413-cit-0001","volume-title":"VIMPAT\u00ae. (lacosamide) Prescribing Information","author":"Anonymous","year":"2014"},{"key":"10.1111\/ane.12413-BIB0002|ane12413-cit-0002","volume-title":"VIMPAT\u00ae. (lacosamide) Summary of Product Characteristics","author":"Anonymous","year":"2014"},{"key":"10.1111\/ane.12413-BIB0003|ane12413-cit-0003","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1124\/mol.107.039867","article-title":"The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels","volume":"73","author":"Errington","year":"2008","journal-title":"Mol Pharmacol"},{"key":"10.1111\/ane.12413-BIB0004|ane12413-cit-0004","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/jnr.23136","article-title":"Comparative study of lacosamide and classical sodium channel blocking antiepileptic drugs on sodium channel slow inactivation","volume":"91","author":"Niespodziany","year":"2013","journal-title":"J Neurosci Res"},{"key":"10.1111\/ane.12413-BIB0005|ane12413-cit-0005","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1527-3458.2007.00001.x","article-title":"Lacosamide: a review of preclinical properties","volume":"13","author":"Beyreuther","year":"2007","journal-title":"CNS Drug Rev"},{"key":"10.1111\/ane.12413-BIB0006|ane12413-cit-0006","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1111\/j.1528-1167.2006.00818.x","article-title":"Effects of the novel antiepileptic drug lacosamide on the development of amygdala kindling in rats","volume":"47","author":"Brandt","year":"2006","journal-title":"Epilepsia"},{"key":"10.1111\/ane.12413-BIB0007|ane12413-cit-0007","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.eplepsyres.2007.03.004","article-title":"Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy","volume":"74","author":"Stohr","year":"2007","journal-title":"Epilepsy Res"},{"key":"10.1111\/ane.12413-BIB0008|ane12413-cit-0008","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1528-1167.2012.03725.x","article-title":"Tolerability, pharmacokinetics, and bioequivalence of the tablet and syrup formulations of lacosamide in plasma, saliva, and urine: saliva as a surrogate of pharmacokinetics in the central compartment","volume":"54","author":"Cawello","year":"2013","journal-title":"Epilepsia"},{"key":"10.1111\/ane.12413-BIB0009|ane12413-cit-0009","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.78.1_MeetingAbstracts.P01.077","article-title":"Low lacosamide plasma protein binding in lacosamide-naive patients","volume":"78","author":"Fountain","year":"2012","journal-title":"Neurology"},{"key":"10.1111\/ane.12413-BIB0010|ane12413-cit-0010","first-page":"254","article-title":"ECG features of sodium channel blockade in rodent phenytoin toxicity and effect of hypertonic saline","volume":"45","author":"Cave","year":"2003","journal-title":"Vet Hum Toxicol"},{"key":"10.1111\/ane.12413-BIB0011|ane12413-cit-0011","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1365-2125.2010.03855.x","article-title":"Effect of lamotrigine on the PR interval in healthy subjects","volume":"71","author":"Dixon","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/ane.12413-BIB0012|ane12413-cit-0012","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/BF00878554","article-title":"Electrophysiological evaluation of the sodium-channel blocker carbamazepine in healthy human subjects","volume":"9","author":"Kenneback","year":"1995","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1111\/ane.12413-BIB0013|ane12413-cit-0013","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/toxsci\/kfm026","article-title":"Preclinical cardiovascular risk assessment in modern drug development","volume":"97","author":"Guth","year":"2007","journal-title":"Toxicol Sci"},{"key":"10.1111\/ane.12413-BIB0014|ane12413-cit-0014","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/978-3-642-25240-2_4","volume-title":"Drug discovery and evaluation: safety and pharmacokinetics assays","author":"Champeroux","year":"2013"},{"key":"10.1111\/ane.12413-BIB0015|ane12413-cit-0015","article-title":"Cardiac safety of lacosamide: a thorough QT\/QTc trial in healthy volunteers","author":"Kropeit","year":"2014","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/ane.12413-BIB0016|ane12413-cit-0016","article-title":"Lacosamide cardiac safety: clinical trials in patients with partial-onset seizures","author":"Rudd","year":"2014","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/ane.12413-BIB0017|ane12413-cit-0017","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ejphar.2005.12.079","article-title":"Effects of cyamemazine on hERG, INa, ICa, Ito, Isus and IK1 channel currents, and on the QTc interval in guinea pigs","volume":"532","author":"Crumb","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1111\/ane.12413-BIB0018|ane12413-cit-0018","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.vascn.2004.06.003","article-title":"Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus\u00a0pattern","volume":"50","author":"Kirsch","year":"2004","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1111\/ane.12413-BIB0019|ane12413-cit-0019","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.vascn.2007.04.005","article-title":"Comparison of guinea-pig ventricular myocytes and dog Purkinje fibres for in\u00a0vitro assessment of drug-induced delayed repolarization","volume":"56","author":"Terrar","year":"2007","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1111\/ane.12413-BIB0020|ane12413-cit-0020","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.0954-6820.1920.tb18266.x","article-title":"Die Systolendauer im Elektrokardiogramm bei normalen Menchen und bei Herzkranken","volume":"53","author":"Fridericia","year":"1920","journal-title":"Acta Med Scand"},{"key":"10.1111\/ane.12413-BIB0021|ane12413-cit-0021","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1476-5381.2011.01415.x","article-title":"On the relationship between block of the cardiac Na(+) channel and drug-induced prolongation of the QRS complex","volume":"164","author":"Harmer","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1111\/ane.12413-BIB0022|ane12413-cit-0022","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.hrthm.2009.08.005","article-title":"Cardiac ion channels in health and disease","volume":"7","author":"Amin","year":"2010","journal-title":"Heart Rhythm"},{"key":"10.1111\/ane.12413-BIB0023|ane12413-cit-0023","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1161\/CIRCEP.108.789081","article-title":"Cardiac ion channels","volume":"2","author":"Grant","year":"2009","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1111\/ane.12413-BIB0024|ane12413-cit-0024","doi-asserted-by":"crossref","DOI":"10.1002\/9780470692561","volume-title":"ECG Interpretation: The Self-Assessment Approach","author":"Abedin","year":"2007"},{"key":"10.1111\/ane.12413-BIB0025|ane12413-cit-0025","volume-title":"Goodman & Gilman's the pharmacological basis of therapeutics","author":"Goodman","year":"2001"},{"key":"10.1111\/ane.12413-BIB0026|ane12413-cit-0026","first-page":"447","article-title":"Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics","volume":"58","author":"Schulz","year":"2003","journal-title":"Pharmazie"},{"key":"10.1111\/ane.12413-BIB0027|ane12413-cit-0027","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1472-8206.2000.tb00398.x","article-title":"Frequency-independent blockade of cardiac Na+ channels by riluzole: comparison with established anticonvulsants and class I anti-arrhythmics","volume":"14","author":"Mestre","year":"2000","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1111\/ane.12413-BIB0028|ane12413-cit-0028","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/bja\/45.5.416","article-title":"The haemodynamic effects of halothane in dogs","volume":"45","author":"Hughes","year":"1973","journal-title":"Br J Anaesth"},{"key":"10.1111\/ane.12413-BIB0029|ane12413-cit-0029","doi-asserted-by":"crossref","first-page":"885","DOI":"10.2460\/ajvr.1997.58.08.885","article-title":"Cardiopulmonary effects of sevoflurane, compared with halothane, enflurane, and isoflurane, in dogs","volume":"58","author":"Mutoh","year":"1997","journal-title":"Am J Vet Res"}],"container-title":["Acta Neurologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fane.12413","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ane.12413\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T14:23:59Z","timestamp":1717856639000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ane.12413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,21]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,11]]}},"URL":"https:\/\/doi.org\/10.1111\/ane.12413","archive":["Portico"],"relation":{},"ISSN":["0001-6314"],"issn-type":[{"value":"0001-6314","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4,21]]}}}